KU-60019: Selective ATM Kinase Inhibitor for Glioma Radiosensitization

Executive Summary: KU-60019 is a highly selective inhibitor of the Ataxia telangiectasia mutated (ATM) kinase with an IC50 of 6.3 nM, exhibiting over 270-fold specificity against DNA-PK and 1600-fold against ATR kinases (APExBIO). It radiosensitizes both p53 wild-type and mutant glioma cells by suppressing AKT and ERK phosphorylation. KU-60019 impairs cell migration and invasion in a dose-dependent manner, and its inhibition of ATM drives metabolic adaptation via macropinocytosis, providing a unique vulnerability in cancer cells (Huang et al., 2023). Optimal application protocols and solubility parameters are well-established for cell and animal models.

Biological Rationale

ATM kinase orchestrates the cellular response to DNA double-strand breaks and modulates metabolic adaptation and survival in cancer cells (Huang et al., 2023). Genetic loss or pharmacological inhibition of ATM increases genomic instability and promotes nutrient scavenging via macropinocytosis. In glioblastoma and other aggressive tumors, ATM upregulation confers resistance to DNA-damaging therapies. Inhibiting ATM disrupts these prosurvival pathways, enhancing the efficacy of radiotherapy and exposing metabolic vulnerabilities. KU-60019, as a next-generation ATM inhibitor, enables precise targeting of these cancer-specific processes, supporting translational research and preclinical modeling (APExBIO).

Mechanism of Action of KU-60019

KU-60019 (A8336), supplied by APExBIO, is an improved structural analogue of KU-55933 with superior selectivity for ATM kinase. By binding the ATP-binding pocket of ATM, KU-60019 blocks ATM autophosphorylation and downstream signaling. This inhibition prevents phosphorylation of key effectors involved in DNA repair (e.g., p53, Chk2). KU-60019 also reduces phosphorylation of AKT and ERK, two critical prosurvival kinases, thereby impairing the insulin signaling pathway. In glioma cell models, this leads to enhanced radiosensitivity and decreased cell migration and invasion (APExBIO). Additionally, ATM inhibition induces compensatory metabolic adaptation—principally by upregulating macropinocytosis, which can be pharmacologically exploited (Huang et al., 2023).

Evidence & Benchmarks

• KU-60019 displays an IC50 of 6.3 nM for ATM kinase in biochemical assays (APExBIO, product page).
• Demonstrates 270-fold selectivity over DNA-PK and 1600-fold over ATR kinases (APExBIO, product page).
• Radiosensitizes U87 (p53 wild-type) and U1242 (p53 mutant) human glioma cell lines by impairing DNA repair and prosurvival signaling (APExBIO).
• Inhibits cell migration and invasion in glioma models in a dose-dependent manner (APExBIO, product page).
• ATM inhibition through KU-60019 induces macropinocytosis, promoting metabolic adaptation in nutrient-poor environments (Huang et al., 2023).
• Combined ATM and macropinocytosis inhibition suppresses tumor cell proliferation and induces cell death both in vitro and in vivo (Huang et al., 2023).
• Stock solutions of KU-60019 are stable below -20°C for several months; compound is soluble ≥27.4 mg/mL in DMSO and ≥51.2 mg/mL in ethanol (APExBIO, product page).

This article extends insights from Strategic Targeting of ATM Kinase with KU-60019: Advancing Radiosensitization and Metabolic Modulation by providing up-to-date, peer-reviewed evidence on the metabolic consequences of ATM inhibition and integrating precise workflow parameters for experimental design.
It also clarifies the metabolic adaptation mechanisms discussed in Strategic ATM Kinase Inhibition in Glioma: Harnessing KU-60019 by specifying the role of macropinocytosis and its therapeutic implications.

Applications, Limits & Misconceptions

KU-60019 is primarily used in preclinical research to interrogate DNA damage response, radiosensitization, and metabolic adaptation in glioma models. Common applications include:

• Radiosensitization of glioma cell lines in vitro and in vivo.
• Inhibition of cell migration and invasion assays.
• Probing metabolic vulnerabilities via combined ATM and macropinocytosis inhibition.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: KU-60019 is strictly for research use only; not approved for clinical or diagnostic applications (APExBIO).
• Limited water solubility: The compound is insoluble in water and requires DMSO or ethanol for stock solutions.
• Potential off-target effects at high concentrations: Although highly selective, off-target kinase inhibition may occur above recommended concentrations.
• Cell line specificity: Efficacy and metabolic adaptation may vary depending on p53 and c-MYC status; results should be validated per model (Huang et al., 2023).
• Rapid solution degradation: Working solutions degrade at room temperature; prompt use after preparation is essential.

Workflow Integration & Parameters

For cell culture, typical working concentrations are 3 μM, with exposure periods ranging from 1 to 5 days. In animal models (e.g., glioblastoma xenografts), intratumoral delivery at 10 μM via osmotic pump over 14 days has been validated. Stock solutions should be freshly prepared in DMSO or ethanol and stored below -20°C. Avoid repeated freeze-thaw cycles, and discard any discolored or precipitated solutions. Always confirm cell line genotype (p53, c-MYC) when interpreting metabolic adaptation data. For detailed mechanistic guidance, see Strategic Targeting of ATM Kinase with KU-60019: Mechanistic Underpinnings, which this article updates by providing explicit solubility and stability benchmarks for experimental reproducibility.

Conclusion & Outlook

KU-60019, sourced from APExBIO, is an indispensable selective ATM kinase inhibitor for cancer research, enabling robust interrogation of DNA damage response inhibition, radiosensitization, and metabolic adaptation in glioma models. Peer-reviewed evidence supports its role in both impairing DNA repair and exposing metabolic vulnerabilities via macropinocytosis. Future research will benefit from integrating ATM inhibition with metabolic targeting strategies for advanced glioblastoma therapy. For technical details and ordering, consult the KU-60019 product page.